by Marisa Wexler, MS | Feb 12, 2026 | Myeloma News
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning the study from a Phase 2 to a pivotal Phase 3 trial. “Following discussions with regulatory agencies,...
by Marisa Wexler, MS | Feb 11, 2026 | Myeloma News
In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel, known for short as lira-cel, lived longer than they were expected to, according to new data announced by developer...
by Marisa Wexler, MS | Feb 10, 2026 | Myeloma News
Anito-cel (anitocabtagene autoleucel), a cell therapy in clinical development as a potential treatment for myeloma, may be less likely to cause side effects than similar, approved myeloma cell therapies, according to a preclinical study. Arcellx, which is developing...
by Andrea Lobo | Feb 9, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech that’s being tested in people with relapsing/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, two aggressive forms of...
by Marisa Wexler, MS | Feb 6, 2026 | Myeloma News
A first-in-human clinical trial will launch in the coming months to test GTB-5550, an immune therapy from GT Biopharma that’s designed to treat various types of cancer, including pancreatic cancer, in patients whose tumors express a protein marker called B7-H3. GT...
by MM360 Staff | Feb 6, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
